Christopher Ogden, Chief Financial Officer at CytomX Therapeutics, Inc. (CTMX), sold 1,624 shares at $3.05 ($5K) on 2026-06-15, disclosed to the SEC on 2026-06-17.
Open-market sale of $5k CTMX by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| Filing → |
| CTMX | SELL | 2025-03-20 | $5K | — | Filing → |
| CTMX | SELL | 2024-08-22 | $2K | — | Filing → |
| CTMX | SELL | 2024-03-21 | $6K | — | Filing → |